ArticleKidney research and clinical practice2026
Nonsteroidal mineralocorticoid receptor antagonist in diabetic kidney disease: mechanistic insights and clinical integration.
Article in Kidney research and clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A new era in diabetic kidney disease therapy: toward remission and survival.Kidney research and clinical practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nonsteroidal mineralocorticoid receptor antagonists (ns-MRA) have emerged as a key therapeutic option for patients with type 2 diabetes and chronic kidney disease, addressing the unmet cardiorenal risk that persists under standard renin-angiotensin system therapy. Finerenone, the most extensively studied ns-MRA, has demonstrated significant reductions in kidney and cardiovascular outcomes across a broad spectrum of CKD severity, with a favorable safety profile. Recent guideline recommendations endorse ns-MRAs in patients with persistent albuminuria despite optimized standard therapy. Moreover, combination strategies with sodium-glucose cotransporter 2 inhibitors show additive benefits, supporting a multi-targeted treatment approach. This review summarizes the pathophysiological rationale, clinical evidence, safety considerations, and combination strategies involving ns-MRAs in contemporary diabetic kidney disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.